As part of a new partnership with Parkinsons UK, the Parkinsons Foundation has granted the nonprofit $250,000 toward a prospective new treatmentlinked to mitochondrial function that is being developed in the Parkinsons Virtual Biotech program. The grant will help advance a project aimed at uncovering new methods of potentially impeding brain cell death through stabilization of the source of energy necessary for cell survival the mitochondria. Continue reading →

I dont want to take away from Mad magazines Alfred E. Neuman or singer-songwriter Bobby McFerrin, but the idea that a pair of rose-colored dont worry glasses will change my life for the better has never sat well with me Continue reading →

Earlier onset of disease, early impairment of memory and thinking, and higher daily use of antiparkinson medication, are associated with increased risk of death related to Parkinsons disease (PD), according to a study that followed newly diagnosed patients for more than 10 years. Conversely, being male, the severity of disease symptoms, and general cognitive ability do not seem to contribute significantly to Parkinsons-related mortality. The study, Overall and Disease Related Mortality in Parkinsons Disease a Longitudinal Cohort Study, was published in the Journal of Parkinsons Disease. Continue reading →

Parkinsons disease is a progressive neurodegenerative disorder affecting one in 350 Australians. Its caused by the loss of cells deep within the brain that produce a neurotransmitter called dopamine. Continue reading →

A surgeon has implanted electrodes in the brain of a patient suffering from severe opioid use disorder, hoping to cure the mans intractable craving for drugs. The device, known as a deep brain stimulator, is designed to alter the function of circuits in the brain. It has been used with varying degrees of success in the treatment of Parkinsons disease, dystonia, epilepsy, obsessive-compulsive disorder and even depression Continue reading →

You may have encountered the term rainmaker used in the nonliteral sense. Lindsay McPhail, editorial director of The Wild Woman Magazine, describes a rainmaker as someone who brings hope to dry and barren places Continue reading →

-- Company stops further development of clinically symptomatic respiratory illness indication but continues development of RTB101 in other aging-related diseases, including Parkinsons disease -- -- Company remains well funded with $117.3 million in cash, cash equivalents and marketable securities as ofSeptember 30, 2019 -- -- Management to host conference call at 8:00 a.m. EST today -- BOSTON, Nov. 15, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today announced that top line data from the PROTECTOR 1 Phase 3 study, evaluating the safety and efficacy of RTB101 in preventing clinically symptomatic respiratory illness (CSRI) in adults age 65 and older, did not meet its primary endpoint, and that it has stopped the development of RTB101 in this indication Continue reading →